Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Lanzillo

Showing results (151-160 of 210) with videos related to

Pageof 21
Sort By:
European Radiology|February 27, 2020
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosisGiuseppe Pontillo, Sirio Cocozza, Martina Di Stasi, et al.
JAMA Neurology|May 3, 2021
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Marta Simone, Pietro Iaffaldano, et al.
Journal of Neuroimmunology|July 30, 2005
The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosisFrancesco Lolli, Benedetta Mazzanti, Marta Pazzagli, et al.
JAMA Neurology|July 1, 2014
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)Marinella Clerico, Irene Schiavetti, Stefania F De Mercanti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2015
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)Roberta Lanzillo, Mario Quarantelli, Carlo Pozzilli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 18, 2021
Disability assessment using Google MapsLuigi Lavorgna, Pietro Iaffaldano, Gianmarco Abbadessa, et al.
Journal of the Neurological Sciences|April 3, 2020
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional studyCamilla Russo, Sirio Cocozza, Eleonora Riccio, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2022
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, Angelo Ghezzi, Clara Guaschino, et al.
Therapeutic Advances in Chronic Disease|August 9, 2021
Digital work engagement among Italian neurologistsFrancesco Brigo, Marta Ponzano, Maria Pia Sormani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 15, 2021
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapyElisabetta Signoriello, Giacomo Lus, Simona Bonavita, et al.
Pageof 21

Showing results (151-160 of 210) with videos related to

Sort By:
Pageof 21
European Radiology|February 27, 2020
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosisGiuseppe Pontillo, Sirio Cocozza, Martina Di Stasi, et al.
JAMA Neurology|May 3, 2021
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Marta Simone, Pietro Iaffaldano, et al.
Journal of Neuroimmunology|July 30, 2005
The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosisFrancesco Lolli, Benedetta Mazzanti, Marta Pazzagli, et al.
JAMA Neurology|July 1, 2014
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)Marinella Clerico, Irene Schiavetti, Stefania F De Mercanti, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2015
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)Roberta Lanzillo, Mario Quarantelli, Carlo Pozzilli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|June 18, 2021
Disability assessment using Google MapsLuigi Lavorgna, Pietro Iaffaldano, Gianmarco Abbadessa, et al.
Journal of the Neurological Sciences|April 3, 2020
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional studyCamilla Russo, Sirio Cocozza, Eleonora Riccio, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 5, 2022
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, Angelo Ghezzi, Clara Guaschino, et al.
Therapeutic Advances in Chronic Disease|August 9, 2021
Digital work engagement among Italian neurologistsFrancesco Brigo, Marta Ponzano, Maria Pia Sormani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 15, 2021
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapyElisabetta Signoriello, Giacomo Lus, Simona Bonavita, et al.
Pageof 21